Study found that clinical trials of cancer drugs shortcomings

Cancer research and drug development will be a better therapy, according to one from Sloan-Kettering Cancer Center researchers published the report pointed out that these test cancer drugs in clinical trials there is a lot of shortcomings.

The published in the February 1 Clinical Cancer Research study, explains why many experimental drugs without the adoption of the final large and expensive clinical testing.

The researchers found that, in their review of the June 2003 to June 2005, a total of 70 Phase II study, only nine on a clear definition of the patients used to assess the benefits of standards. These studies generally contain 30 to 50 patients, the goal is to assess whether to continue the large-scale Phase III clinical trial, which is to decide whether the drug can be used for patients with cancer of the final test.

The researchers pointed out that this is in the clinical trial testing led to the problem, because even when the drug has changed, researchers are still using the same old methods to measure the effectiveness of these drugs. So the researchers suggested that when the pharmaceutical companies or laboratories for new material for clinical trials, we must set up a new assessment criteria, can more effectively assess the efficacy and safety of drugs.